Clinical trials: Hepatocellular Carcinomas
Hepatocellular Carcinoma
Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
This is a clinical trial that aims to evaluate whether adding a bile acid called tauroursodeoxycholic acid (TUDCA) can improve the effects of immunotherapy in patients with advanced liver cancer (hepatocellular carcinoma).
- Trial name
- NCT07064668
- Testing
- TUDCA (Tauroursodeoxycholic Acid) Supplementation, Immune checkpoint inhibitor (ICI)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma, Postoperative Infection
Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver Resection
This trial is a multi-center, double-blinded, randomized (1:1) clinical trial. The aim is to compare the postoperative infection rate between the 3 days postoperative AMP group and the placebo group in HCC patients undergoing…
- Trial name
- HCC (NCT03990974)
- Testing
- postoperative antimicrobial prophylaxis, No postoperative antimicrobial prophylaxis
- Where
- China
- Volunteers
- 458 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Study on the Safety and Efficacy of BST06 Injection in the Treatment of Advanced Hepatocellular Carcinoma
The study is an exploratory clinical trial initiated by an open, single arm researcher to evaluate the safety, tolerability, and preliminary efficacy of BST06 injection in the treatment of advanced hepatocellular carcinoma in…
- Trial name
- NCT06645314
- Testing
- Group A, Group B
- Volunteers
- 16 people
- Sponsor
- BioSyngen Pte Ltd
Hepatocellular Carcinoma
A Phase II Study of Radiotherapy for Locally Advanced Hepatocellular Carcinoma (HCC)
1. This is a phase II study of radiotherapy for patients with locally advanced HCC. 2. Patients whose tumor(s) are not suitable for other local treatment, such as surgery, trans-arterial chemoembolization (TAE), ethanol…
- Trial name
- NCT00154817
- Testing
- radiotherapy
- Volunteers
- 12 people
- Sponsor
- National Taiwan University Hospital
Breast Cancer, Lung Cancer
hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 or INO-1401 alone or in combination with INO-9012, delivered by electroporation in subjects with high-risk solid tumor…
- Conditions
- Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Cancer
- Trial name
- TRT-001 (NCT02960594)
- Testing
- INO-1400, INO-9012, INO-1401
- Where
- 6 sites in United States
- Volunteers
- 93 people
- Sponsor
- Inovio Pharmaceuticals
HepatoCellular Carcinoma
HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial
Hepatic artery infusion of oxaliplatin, leucovorin and 2400 mg/m² fluorouracil is effective in hepatocellular carcinoma. However, SILIUS study showed that sorafenib plus hepatic artery infusion of cisplatin and fluorouracil did…
- Trial name
- NCT04667351
- Testing
- 2400 mg/m² 5-fu, 1200 mg/m² 5-fu
- Where
- 3 sites in China
- Volunteers
- 400 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Liver Cancer
Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma
Hepatocellular cancer is the 6th most common seen disease in the world and the 3rd in cancer-related deaths. Liver transplantation is the primary curative treatment of HCC, as it eliminates liver cancer and underlying cirrhosis.
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Advanced Adult Hepatocellular Carcinoma, Cirrhosis, Liver
- Trial name
- NCT04576572
- Where
- Turkey (Türkiye)
- Volunteers
- 424 people
- Sponsor
- Inonu University
Hepatocellular Carcinoma
Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common liver primary cancer with a high rate of mortality. Since the results of IMbrave150, immunotherapy have emerged as a standard of care for HCC patients advanced and/or unresectable…
- Trial name
- MOTHER (NCT06551272)
- Testing
- EXL01
- Where
- 6 sites in France
- Volunteers
- 34 people
- Sponsor
- Center Eugene Marquis
Hepatocellular Carcinoma
Comparison of Microwave and Radiofrequency Ablation for Liver
According to randomized controlled trial requirement, the therapeutic effectiveness of cooled-probe microwave ablation and radiofrequency ablation on early-stage hepatocellular carcinoma is compared to find a better approach for…
- Trial name
- NCT02539212
- Testing
- microwave ablation, radiofrequency ablation
- Where
- China
- Volunteers
- 403 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT05256381
- Testing
- Nanrilkefusp Alfa, Pembrolizumab
- Where
- 54 sites in United States, Belgium and 7 more
- Volunteers
- 166 people
- Sponsor
- SOTIO Biotech AG
Hepatocellular Carcinoma by AJCC Stage
Performance Evaluation (Sensitivity/Specificity) of HelioLiver Test for Detection of HCC
De-identified whole blood and serum samples are collected for the purpose of evaluating the performance (sensitivity/specificity) of the HelioLiver Test for the detection of hepatocellular carcinoma (HCC).
- Trial name
- ENCORE (NCT05059665)
- Testing
- Helio Liver Test
- Where
- 2 sites in China
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Helio Genomics
Hepatic Carcinoma Malignant Primary Non-Resectable
Liquid Biopsy in Hepatocellular Carcinoma
Circulating tumor DNA (ctDNA) carrying tumor-specific sequence alterations has been found in the cell-free fraction of blood. Hepatocellular carcinoma (HCC) specimens are difficult to obtain, and noninvasive methods are required…
- Trial name
- HCCGenePanel (NCT04111029)
- Testing
- Cell Free DNA
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Hepatocellular Carcinoma
Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma
The purpose of this study is to determine that Gemcitabine(GEM) plus oxaliplatin(OXA) (GEMOX) is superior to Oxaliplatin Plus Fluorouracil/Leucovorin(FOLFOX4) in prolonging progression-free survival（PFS） in patients with Advanced…
- Trial name
- NCT02534337
- Testing
- GEMOX, FOLFOX4
- Sponsor
- Guangxi Medical University
Cancer of Liver
Incorporation of Protein Induced by Vitamin K Absence or Antagonist-II Into Transplant Criteria Expands Beneficiaries of Liver Transplantation for Hepatocellular Carcinoma
This is a multi-center study in China to investigate the role of PIVKA-II in HCC recipient selection and prognostic stratification by analyzing the data of 522 recipients with HCC registered in the China Liver Transplant Registry.
- Trial name
- NCT05907772
- Testing
- No intervention
- Where
- China
- Volunteers
- 522 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma
Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma (HCC)
The purpose of this study is to determine efficacy of SB injection in Hepatocellular Carcinoma (HCC).
- Trial name
- HCC (NCT01308645)
- Testing
- SB injection
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- SBPharmaceutical IND, Co., LTD
Advanced Hepatocellular Carcinoma (HCC)
Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma
The goal of this open-label, single-arm phase I/II clinical trial is to evaluate the feasibility, safety, and anti-tumor efficacy of the autologous neoantigen-specific T-cell therapy (iNeo-Vac-T01) in patients with advanced…
- Trial name
- NCT07123545
- Testing
- iNeo-Vac-P01 Personalized Neoantigen Peptide Vaccine, iNeo-Vac-T01 Personalized T Cell Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma, Liver Cancer
Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular Carcinoma
Rationale: Patients diagnosed with hepatocellular carcinoma (HCC) at an intermediate or advanced stage (according to the BCLC classification system) are not amenable of curative treatment.
- Trial name
- NCT00910572
- Testing
- Yttrium-90 microspheres (Therasphere MDS Nordion)
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Cirrhoses, Liver, Carcinoma Liver
ProspEXPO : Study of the Associations Between Hepatocellular Carcinoma and Chemical and Psychosocial Environmental EXPOsome
The aim of the study is to build up a bio-collection of biological samples from patients with cirrhosis. Further work using this bio-collection will permit to describe the influence of different exposome factors (nutrition…
- Trial name
- ProspEXPO (NCT07119957)
- Testing
- Blood, urine and stool biocollection
- Where
- 4 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Angers
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT05824975
- Testing
- GI-102 subcutaneous (SC), GI-102, doxorubicin
- Where
- 11 sites in United States, South Korea
- Volunteers
- 358 people
- Sponsor
- GI Innovation, Inc.
Hepatocellular Carcinoma
Prevention of Hand-foot Skin Reaction
Sorafenib-induced hand-foot skin reaction (HFSR) is a dose-dependent side effect in patients with advance hepatocellular carcinoma (HCC).
- Trial name
- NCT04568330
- Testing
- best support care, moisture cream, 10% urea-based cream
- Volunteers
- 129 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan